Anterior chamber factors identified for OAG

Article

Anterior chamber depth (ACD) and anterior chamber angle (ACA) were the factors identified relating to the progression of open-angle glaucoma (OAG).

Anterior chamber depth (ACD) and anterior chamber angle (ACA) were the factors identified relating to the progression of open-angle glaucoma (OAG).

A group led by Dr Zhiying Pan, Department of Ophthalmology, Interdisciplinary School of Medicine and Engineering, University of Yamanashi, Chuo Yamanashi, Japan, included 157 glaucoma patients and 26 pseudophakic eye patients used as controls in the analysis.

The team used a scanning peripheral ACD analyzer to assess ACD by numeric grades ACDG 1 to 12 and ACA twice during 2003 and 2008. The exclusion criteria was history of laser or incisional surgery, other ocular diseases that may affect visual field, visual acuity less than 20/30 and treatment with pilocarpine ophthalmic solution.

ACDG and ACA reduced from 7.2±2.3 to 6.5±2.1 and 34.2±12.6 to 28.1±10.3, respectively in the glaucoma patients, but there were no significant changes observed in patients who underwent cataract surgery.

ACD changes were greater at the peripheral region than at the central region and the reduction in ACDG was strongly linked to deep initial ACDG and wide ACA. Rapid visual field deterioration was found in patients that had a shallow ACDG and narrow ACA.

Overall, ACDG and ACA declined with age and initial ACDG and ACA was linked to OAG progression over time.The paper for this study can be found in the Journal of Glaucoma.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.